Systemic and Other System Disorders

[摘要] NATURAL HISTORY OF EOSINOPHILIA-MYALGIA SYNDROMECulpepper RC, Williams RG, Mease PJ, Koepsell TD, Kobayashi JM. Ann Intern Med. 1991;115:437-442Purpose of the StudyTo examine the natural history of the eosinophilia-myalgia syndrome and to assess the effects of oral corticostenoids on the course of this disorder.Study PopulationA cohort of 47 patients were reported to the Washington State Department of Health who had met the Centers for Disease Control (CDC) criteria for eosinophilia-myalgia syndrome with onset of symptoms between July 1 and December 12, 1989. Two of these 47 could not be interviewed, leaving only 45 for the final study. Features of these cases of eosinophilia-myalgia syndrome were in accordance with the CDC definitions and included an eosinophil count of greater than 1 billion cells per liter, generalized myalgia of sufficient severity to affect activities of daily living, and absence of any infection or neoplasm that could account for the illness.MethodsThese 45 patients were followed up with telephone interviews on four occasions over a period of 12 months after their initial diagnosis of eosinophilia-myalgia syndrome. Patients answered questions about their history of l-tryptophan use, symptom onset and resolution, and maximal severity of each of their symptoms. Information was collected from their primary physicians regarding physical examination findings and types/effectiveness of any treatments given.FindingsPatients were predominantly non-Hispanic white women (87%) with an average age of 49 years, all of whom had taken an l-tryptophan product prior to disease onset. Symptoms typically progressed from early onset of myalgia (100%) and fatigue (96%) to other symptoms such as peripheral edema (93%), cough or dyspnea (80%), rash (80%), paresthesias or weakness (76%), and scleroderma-like skin changes (42%).

[学科分类] 儿科学